Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

Leonie Voorwerk(The Netherlands Cancer Institute), Marleen Kok(The Netherlands Cancer Institute)

Nature Medicine

May 13, 2019

10.1038/s41591-019-0432-4

Cited by 878

Related Papers

Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023

|Annals of Oncology|2023|218

Prognosis and tumor-infiltrating lymphocytes (TILs) in estrogen receptor (ER)-low metastatic breast cancer (MBC): Analysis from a large multi-institutional cohort and the TONIC phase II trial with nivolumab.

|Journal of Clinical Oncology|2024|1

Prognosis and Biological Characteristics of ER-Low Metastatic Breast Cancer: Results from a Multicenter Cohort and the TONIC Trial

|Clinical Cancer Research|2025|1

Abstract PS14-09: Central Nervous System as the Primary Site of First Relapse in Patients with Triple-Negative Breast Cancer Achieving Pathological Complete Response After Neoadjuvant Treatment

|Clinical Cancer Research|2025|0

Supplementary Table S3 from Prognosis and Biological Characteristics of ER-Low Metastatic Breast Cancer: Results from a Multicenter Cohort and the TONIC Trial

|Unknown|2025|0